EnPlusOne Biosciences, a biotechnology company harnessing the power of enzymes to deliver better RNA at scale, announced the appointment of Clare Murray, Ph.D., as Chief Executive Officer.
Dr. Murray brings deep experience in corporate strategy and business development, having led multiple transactions with global pharmaceutical and innovative biotechnology companies. Her work forging strategic partnerships with CDMOs aligns directly with EnPlusOne’s roadmap to scale manufacturing and deliver RNA therapeutics with greater efficiency and precision.
“We are thrilled to attract an extraordinary executive like Clare as EnPlusOne reaches an inflection point in its growth trajectory,” said Steven Kasok, Chair of the EnPlusOne Board of Directors. “Clare’s track record in company building and strategic partnerships makes her the ideal leader to guide us through our next phase of development as we accelerate commercialization of our ezRNA™ synthesis platform.”
Also Read: EveryONE Medicines Announces Appointment of Michelle L. Mellion, MD, as Chief Medical Officer
The appointment caps a period of increasing traction for EnPlusOne, which is actively partnering across the RNA therapeutic landscape to solve key manufacturing challenges, including achieving scale in siRNA, purity in gRNA synthesis, and novel RNA therapeutic design through enabling modifications. EnPlusOne’s novel, template-free, aqueous-based, enzymatic RNA synthesis technology is setting a new standard for sustainable, scalable RNA manufacturing and design.
“I’m excited to lead EnPlusOne at a time when the demand for high-quality RNA is surging,” said Dr. Murray. “The team has built a truly differentiated technology that solves long-standing barriers to scale in siRNA and CRISPR therapeutics manufacturing. I look forward to expanding our commercial reach and helping realize the full potential of EnPlusOne’s platform.”
SOURCE: Businesswire